Navid Khan

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial

Laurent Servais, Eugenio Mercuri, Volker Straub et al. · Nucleic Acid Therapeutics · 2021 · 114 citations · Full text

Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial

Craig M. McDonald, Perry B. Shieh, Hoda Abdel‐Hamid et al. · Journal of Neuromuscular Diseases · 2021 · 107 citations · Full text

Preclinical Therapeutics, Translational Medicine, Adverse Events +12

Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy

Navid Khan, Helen Eliopoulos, Lixin Han et al. · Journal of Neuromuscular Diseases · 2019 · 93 citations · Full text

Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls

Jerry R. Mendell, Navid Khan, Nanshi Sha et al. · Journal of Neuromuscular Diseases · 2021 · 48 citations · Full text

A novel primary amine-based anion exchange membrane adsorber

Maybelle Woo, Navid Khan, Jonathan Royce et al. · Journal of Chromatography A · 2011 · 38 citations

Anion Sensing, Chemical Engineering, Membrane Formation